Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rosalba Mansi

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
EJNMMI Research|April 6, 2024
In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [<sup>177</sup>Lu]Lu-PP-F11N in humans: the lumed phase 0b studyChristof Rottenburger, Michael Hentschel, Markus Fürstner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 18, 2024
<sup>61</sup>Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human ImagingTais Basaco Bernabeu, Rosalba Mansi, Luigi Del Pozzo, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 18, 2016
Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patientsTheodosia Maina, Mark W Konijnenberg, Petra KolencPeitl, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 28, 2011
Comparison of the binding and internalization properties of 12 DOTA-coupled and ¹¹¹In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607Luigi Aloj, Michela Aurilio, Valentina Rinaldi, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
EJNMMI Research|April 6, 2024
In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [<sup>177</sup>Lu]Lu-PP-F11N in humans: the lumed phase 0b studyChristof Rottenburger, Michael Hentschel, Markus Fürstner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 18, 2024
<sup>61</sup>Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human ImagingTais Basaco Bernabeu, Rosalba Mansi, Luigi Del Pozzo, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 18, 2016
Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patientsTheodosia Maina, Mark W Konijnenberg, Petra KolencPeitl, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 28, 2011
Comparison of the binding and internalization properties of 12 DOTA-coupled and ¹¹¹In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607Luigi Aloj, Michela Aurilio, Valentina Rinaldi, et al.
Pageof 6